We compared MIA serum levels in two groups of patients with primary melanoma; those with positive as opposed to those with negative sentinel lymph nodes.
We compared 3 tumor markers, TA90-immune complex (TA90IC), melanoma-inhibiting activity (MIA) protein, and S100B protein in Stage III melanoma patients undergoing adjuvant vaccine immunotherapy.
The goal of this study was to determine the effect of ultraviolet radiation (UVR), activating ras mutation, or loss of p53 function on MIA expression and release from melanoma cells.
Melanoma inhibitory activity, secreted by melanoma cells, is known to inhibit tumour cell attachment to the extracellular matrix enhancing their invasive potential.